The Penetration of Renal Mass Biopsy in Daily Practice: A Survey Among Urologists

Barwari, Kurdo; Rosette, Jean J. de la; Laguna, M. Pilar

doi:10.1089/end.2011.0407

Cited by 47 publications

(29 citation statements)

References 21 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The development of a non-invasive “liquid biopsy” represents a significant innovation in the field of precision medicine. It is capable of replacing, or at least augmenting the use of invasive biopsy which has limited success and associated complications [3, 4]. Liquid biopsies, owing to their minimally invasive nature, are associated with significantly less morbidity and can be scheduled more frequently to provide a personalized snapshot of disease at successive time points.…”

Section: Introductionmentioning

confidence: 99%

Liquid biopsy: a step forward towards precision medicine in urologic malignancies

et al. 2017

View full text Add to dashboard Cite

There is a growing trend towards exploring the use of a minimally invasive “liquid biopsy” to identify biomarkers in a number of cancers, including urologic malignancies. Multiple aspects can be assessed in circulating cell-free DNA, including cell-free DNA levels, integrity, methylation and mutations. Other prospective liquid biopsy markers include circulating tumor cells, circulating RNAs (miRNA, lncRNAs and mRNAs), cell-free proteins, peptides and exosomes have also emerged as non-invasive cancer biomarkers. These circulating molecules can be detected in various biological fluids, including blood, urine, saliva and seminal plasma. Liquid biopsies hold great promise for personalized medicine due to their ability to provide multiple non-invasive global snapshots of the primary and metastatic tumors. Molecular profiling of circulating molecules has been a stepping-stone to the successful introduction of several non-invasive multi-marker tests into the clinic. In this review, we provide an overview of the current state of cell-free DNA-based kidney, prostate and bladder cancer biomarker research and discuss the potential utility other circulating molecules. We will also discuss the challenges and limitations facing non-invasive cancer biomarker discovery and the benefits of this growing area of translational research.

show abstract

Section: Introductionmentioning

confidence: 99%

Liquid biopsy: a step forward towards precision medicine in urologic malignancies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…These results were similar to the results in our survey where 67% of responding institutions performed core biopsies, 5% performed FNA, and 28% performed both core biopsy and FNA. 15 Ninety-five percent of the institutions in our study and 92% of respondents in the study by Barwari et al who performed a biopsy of the tumor used core biopsy or a combination of core biopsy with FNA. In our survey we also asked when the biopsy was performed (prior to the day of the procedure or on the day of the procedure prior to ablation) to determine whether knowledge of the biopsy result was known prior to thermal ablation.…”

Section: Discussionmentioning

confidence: 64%

“…4 Barwari et al sent a questionnaire to members of the Endourological Society to assess the use of renal mass biopsy in current urologic practice. 15 Despite a low response rate (10.2%, 190 responders), they found that 73% of responders ''never'' or ''rarely'' performed a renal mass biopsy. Tan et al evaluated patient and tumor characteristics associated with percutaneous renal mass biopsy among patients with small renal masses at a single institution.…”

Section: Discussionmentioning

confidence: 95%

Ablation of Small Renal Masses: Practice Patterns at Academic Institutions in the United States

Patel

Abel

Hedican

et al. 2013

Journal of Endourology

View full text Add to dashboard Cite

show abstract

“…A survey among urologists has shown that the use of RMB in characterisation of the renal mass remains limited at present, with only a minority of clinicians using biopsy in their practice . Cost‐effectiveness models have been developed to further evaluate the potential impact of RMB.…”

Section: Resultsmentioning

confidence: 99%

Small renal mass biopsy – how, what and when: report from an international consensus panel

et al. 2014

View full text Add to dashboard Cite

To discuss the use of renal mass biopsy (RMB) for small renal masses (SRMs), formulate technical aspects, outline potential pitfalls and provide recommendations for the practicing clinician. The meeting was conducted as an informal consensus process and no scoring system was used to measure the levels of agreement on the different topics. A moderated general discussion was used as the basis for consensus and arising issues were resolved at this point. A consensus was established and lack of agreement to topics or specific items was noted at this point. Recommended biopsy technique: at least two cores, sampling different tumour regions with ultrasonography being the preferred method of image guidance. Pathological interpretation: ‘non‐diagnostic samples’ should refer to insufficient material, inconclusive and normal renal parenchyma. For non‐diagnostic samples, a repeat biopsy is recommended. Fine‐needle aspiration may provide additional information but cannot substitute for core biopsy. Indications for RMB: biopsy is recommended in most cases except in patients with imaging or clinical characteristics indicative of pathology (syndromes, imaging characteristics) and cases whereby conservative management is not contemplated. RMB is recommended for active surveillance but not for watchful‐waiting candidates. We report the results of an international consensus meeting on the use of RMB for SRMs, defining the technique, pathological interpretation and indications.

show abstract

The Penetration of Renal Mass Biopsy in Daily Practice: A Survey Among Urologists

Abstract: RMB is not yet applied widely in urologic practice, with academic urologists performing RMB less infrequently. Core biopsies are still preferred, although combined with cytologic punctures by a considerable number of responders.

Cited by 47 publications

References 21 publications

Liquid biopsy: a step forward towards precision medicine in urologic malignancies

Liquid biopsy: a step forward towards precision medicine in urologic malignancies

Ablation of Small Renal Masses: Practice Patterns at Academic Institutions in the United States

Small renal mass biopsy – how, what and when: report from an international consensus panel

Contact Info

Product

Resources

About